102 related articles for article (PubMed ID: 22714999)
1. Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Chen SJ; Zhou GB
IUBMB Life; 2012 Aug; 64(8):671-5. PubMed ID: 22714999
[TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
3. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Zhou GB; Li G; Chen SJ; Chen Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1434-49. PubMed ID: 17723177
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
5. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
6. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
8. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Komatsu N
Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
[No Abstract] [Full Text] [Related]
9. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
10. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
He LZ; Merghoub T; Pandolfi PP
Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
[TBL] [Abstract][Full Text] [Related]
11. APL, a model disease for cancer therapies?
de Thé H; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7136-9. PubMed ID: 11704841
[No Abstract] [Full Text] [Related]
12. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
Altucci L; Rossin A; Raffelsberger W; Reitmair A; Chomienne C; Gronemeyer H
Nat Med; 2001 Jun; 7(6):680-6. PubMed ID: 11385504
[TBL] [Abstract][Full Text] [Related]
13. The role of PML in hematopoietic and leukemic stem cell maintenance.
Nakahara F; Weiss CN; Ito K
Int J Hematol; 2014 Jul; 100(1):18-26. PubMed ID: 24488785
[TBL] [Abstract][Full Text] [Related]
14. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Puccetti E; Güller S; Orleth A; Brüggenolte N; Hoelzer D; Ottmann OG; Ruthardt M
Cancer Res; 2000 Jul; 60(13):3409-13. PubMed ID: 10910048
[TBL] [Abstract][Full Text] [Related]
16. Molecular targets and the treatment of myeloid leukemia.
Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
18. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.
Zhen T; Wu CF; Liu P; Wu HY; Zhou GB; Lu Y; Liu JX; Liang Y; Li KK; Wang YY; Xie YY; He MM; Cao HM; Zhang WN; Chen LM; Petrie K; Chen SJ; Chen Z
Sci Transl Med; 2012 Mar; 4(127):127ra38. PubMed ID: 22461642
[TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukemia (AML-M3)--Part 2: Molecular defect, DNA diagnosis, and proposed models of leukemogenesis and differentiation therapy.
Randolph TR
Clin Lab Sci; 2000; 13(2):106-16. PubMed ID: 11066449
[TBL] [Abstract][Full Text] [Related]
20. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]